Atopic Dermatitis Primer for AAD 2025: Dermatologist Mona Shahriari, MD, Explains the Rise in Prevalence
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
Dupilumab Reduces Specific IgE to Foods at 12 and 24 Months in Small Study
AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.
FDA Clears Google Pixel Watch 3 Loss of Pulse Detection Feature
The Loss of Pulse Detection feature will begin rolling out in the US late next month.
Nektar Therapeutics Completes Enrollment for Phase 2b Alopecia Areata Trial
The company announced completion of target enrollment in the REZOLVE-AA study of rezpegaldesleukin in people with severe-to-very-severe alopecia areata.
FDA Greenlights New Wearable Treatment for Parkinson Disease: Daily Dose
Your daily dose of the clinical news you may have missed.
Perimenopause Symptoms May Affect More Than Half of Women as Young as Age 30
Although many women experience symptoms of perimenopause between ages 30 and 35, the majority do not seek medical attention for up to 2 decades, a new study reveals.
American Academy of Dermatology 2025 Prep: A Dermatologist Considers When Atopic Dermatitis Referral from Primary Care is Indicated
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
The Superbug Challenge: Medicine's Essential Fight Against Antimicrobial Resistance
A medical director of antimicrobial stewardship at a large metropolitan health system highlights the dangers of AMR and how she believes the pharmaceutical industry could help.
Measles Outbreak Explained: Disease History, Vaccine Breakthrough and 2025 Resurgence
The 2025 measles outbreak in Texas has reignited discussion surrounding vaccine-preventable diseases and the importance of maintaining high immunization rates.
Study Finds Telehealth Use in Depression Skews Towards Higher-Wealth Patients
Patients with depression from high-wealth areas were 1.62 times more likely in primary care and 1.67 times more likely in psychiatry to use telehealth.
FDA Accepts Supplemental New Drug Application for Uzedy for Bipolar I Disorder
The FDA accepted the sNDA for risperidone (Uzedy) extended-release injectable suspension for the maintenance treatment of bipolar I disorder in adults.
Transdermal Peanut Patch Shows Lasting Allergy Benefits: Daily Dose
Focus on AAD 2025: Dermatologist Mona Shahriari, MD, Highlights the PCP Role in Atopic Dermatitis Care
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.
Zonisamide Shows Promise for Hard-to-Treat Migraine in Children, Adolescents
While the data on zonisamide efficacy for migraine in youths is preliminary, all study participants experienced a 66% reduction in headaches after 1 month of treatment.
Measles Claims Life of Unvaccinated Texas Schoolchild, First US Fatality Reported Since 2015
A rural west Texas "undervaccinated" Mennonite community is the epicenter of the worst measles outbreak in the state in 30 years, the state health department reported.
Would you Know Measles if You Saw It?
A case of measles is a very rare diagnosis in the 21st century, but as MMR vaccination rates fall, the cases climb. Would you recognize the signs & symptoms?
FDA Approves Pentavalent Meningococcal Vaccine Penmenvy: Daily Dose
Home-Based Therapy Achieves 100% Success Rate in Children with High-Threshold Peanut Allergy
AAAAI 2025: Phase 2 study results showed POIT with home-measured peanut products was not only highly effective but also posed few risks.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
New neffy (epinephrine nasal spray) Data To Be Shared in 9 Presentations at 2025 AAAAI
Data on the epinephrine nasal spray will include findings from an efficacy study comparing anaphylaxis symptoms during oral food challenge, according to ARS.